Mitlak B - Search Results

1

Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.

Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B. Reginster JY, et al. Among authors: mitlak b. Osteoporos Int. 2006 Jan;17(1):1-7. doi: 10.1007/s00198-005-1984-3. Epub 2005 Aug 10. Osteoporos Int. 2006. PMID: 16091835

2

Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend.

Cosman F, Hans D, Shevroja E, Wang Y, Mitlak B. Cosman F, et al. Among authors: mitlak b. J Bone Miner Res. 2023 Apr;38(4):464-470. doi: 10.1002/jbmr.4764. Epub 2023 Feb 12. J Bone Miner Res. 2023. PMID: 36588166 Free article. Clinical Trial.

3

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Delmas PD, et al. Among authors: mitlak bh. N Engl J Med. 1997 Dec 4;337(23):1641-7. doi: 10.1056/NEJM199712043372301. N Engl J Med. 1997. PMID: 9385122 Free article. Clinical Trial.

4

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Ettinger B, et al. Among authors: mitlak bh. JAMA. 1999 Aug 18;282(7):637-45. doi: 10.1001/jama.282.7.637. JAMA. 1999. PMID: 10517716 Clinical Trial.

5

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Neer RM, et al. Among authors: mitlak bh. N Engl J Med. 2001 May 10;344(19):1434-41. doi: 10.1056/NEJM200105103441904. N Engl J Med. 2001. PMID: 11346808 Free article. Clinical Trial.

6

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.

Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C. Bjarnason NH, et al. Among authors: mitlak b. Osteoporos Int. 2001;12(11):922-30. doi: 10.1007/s001980170020. Osteoporos Int. 2001. PMID: 11808544 Clinical Trial.

7

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH. Kaufman JM, et al. Among authors: mitlak bh. Osteoporos Int. 2005 May;16(5):510-6. doi: 10.1007/s00198-004-1713-3. Epub 2004 Aug 18. Osteoporos Int. 2005. PMID: 15322742 Clinical Trial.

8

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.

Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH. Lindsay R, et al. Arch Intern Med. 2004 Oct 11;164(18):2024-30. doi: 10.1001/archinte.164.18.2024. Arch Intern Med. 2004. PMID: 15477438 Clinical Trial.

9

Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.

Abadie EC, Devogealer JP, Ringe JD, Ethgen DJ, Bouvenot GM, Kreutz G, Laslop A, Orloff JJ, Vanderauwera PM, Delmas PD, Dere WH, Branco J, Altman RD, Avouac BP, Menkes CJ, Vanhaelst L, Mitlak BH, Tsouderos Y, Reginster JY. Abadie EC, et al. Semin Arthritis Rheum. 2005 Aug;35(1):1-4. doi: 10.1016/j.semarthrit.2005.03.006. Semin Arthritis Rheum. 2005. PMID: 16084217 Review.

10

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.

Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH. Delmas PD, et al. Among authors: mitlak bh. Bone. 2006 Aug;39(2):237-43. doi: 10.1016/j.bone.2006.02.003. Epub 2006 Mar 24. Bone. 2006. PMID: 16563890 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

96 results

Search Page